Antifungal antibiotics

@article{Gupte2001AntifungalA,
  title={Antifungal antibiotics},
  author={Monali Gupte and Prasad M. Kulkarni and Babu Ganguli},
  journal={Applied Microbiology and Biotechnology},
  year={2001},
  volume={58},
  pages={46-57}
}
Abstract. The search for new drugs against fungal infections is a major challenge to current research in mycotic diseases. The present article reviews the current types of antifungal infections, the current scenario of antifungal antibiotics, and the need and approaches to search for newer antifungal antibiotics and antifungal drug targets. 

Tables and Topics from this paper

Emergence of Candida spp. and exploration of natural bioactive molecules for anticandidal therapy –status quo
TLDR
The exploration of drugs from natural resources serves as a better alternative source in anticandidal therapeutics, having great scope for drug discovery in the future. Expand
Antimicrobial natural products
TLDR
This chapter has primarily focused into antimicrobial compounds developed through natural routes that are currently available as antibiotics for clinical uses and/or are at various developmental stages within the drug development pipeline for potential treatment of minor and life threatening infections. Expand
Antibiotics business: A glimpse
TLDR
The emergence and spread of antibiotic resistant pathogens has increased substantially over the past two decades, and the development of new antibiotics has decreased alarmingly, because pharmaceutical companies are pulling out of antibiotic research. Expand
Antifungal peptides: Biosynthesis, production and applications
TLDR
Antifungal peptides are excellent models for drug discovery exhibiting unique characteristics such as high specifi city, broad spectrum, low level of resistance reaching and unique mode of action. Expand
Isolation investigation of Antifungal activity of Soil Actinomycetes
  • 2015
Infection caused by dermatophytic fungi in man and animals is common throughout the world. Dermatophytoses poses a serious concern to the economically poor population of India. Fungi cause bothExpand
A small protein that fights fungi: AFP as a new promising antifungal agent of biotechnological value
  • V. Meyer
  • Biology, Medicine
  • Applied Microbiology and Biotechnology
  • 2008
TLDR
This review summarises the current knowledge of the structure, mode of action and expression of AFP, and highlights similarities and differences concerning these issues between AFP and its related proteins from other Ascomycetes. Expand
[Antimicrobial activity of a Saharan Streptomyces spp. PAL111 strain against various clinical and toxinogenic microorganisms resistant to antibiotics].
TLDR
The strong activity of isolate PAL111 against the pathogenic microorganisms and the polar characteristic of the produced antibiotic could encourage further studies on this bioactive molecule. Expand
Sub-MICs of Carum copticum and Thymus vulgaris influence virulence factors and biofilm formation in Candida spp
TLDR
The findings have highlighted the concentration dependent activity of oils of C. copticum and T. vulgaris against virulence factors and biofilms in proteinase and haemolysin producing drug-resistant strains of Candida spp. Expand
Production of a growth dependent metabolite active against dermatophytes by Streptomyces rochei AK 39.
TLDR
The metabolite from Streptomyces rochei AK 39 was produced during late log phase and was active against only dermatophytes with a greater potency than griseofulvin, however, this needs further investigation using purified powdered form of the active component. Expand
Anti-Candida activity of geraniol involves disruption of cell membrane integrity and function.
TLDR
The results suggest that geraniol disrupts cell membrane integrity by interfering with ergosterol biosynthesis and inhibiting the very crucial PM-ATPase, which may hence be used in the management and treatment of both superficial and invasive candidiasis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 98 REFERENCES
New potential targets for antifungal development
TLDR
This review discusses how such approaches are being developed through the identification of novel biochemical and molecular targets to meet the challenges imposed by the scientific research in medical mycology. Expand
The fungal cell wall as a drug target.
TLDR
Inhibitors of the synthesis of one cell-wall component, beta-(1,3)-glucan, are currently under development as antifungal and antipneumocystis agents. Expand
Human mycoses: drugs and targets for emerging pathogens.
Fungal infections in humans range flom superficial and cutaneous (such as dermatophytoses) to deeply invasive and dissemi hated (such as candidiasis and cryptococcosis). Pathogenic fungi occurExpand
The new fungal opportunists are coming.
  • J. Perfect, W. Schell
  • Biology, Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1996
TLDR
This discussion addresses several issues of pathogenesis, epidemiology, diagnosis, and treatment with regard to these new opportunists, through a review of both general and specific concepts. Expand
Emerging novel antifungal agents.
TLDR
Most of these compounds identified are novel substrates for synthetic modifications that could lead to the discovery of future antifungal drugs, but factors such as a narrow spectrum of activity, susceptibility to efflux pumps, protein binding, serum inactivation and poor pharmaceutical properties prevent their use in the clinic. Expand
Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches.
TLDR
Using the current understanding of the mechanisms of drug resistance as a template, several strategies to overcome resistance have been identified and the development of new antifungal drugs is likely to have the most significant future impact on the management of drug resistant fungi in fungal infections. Expand
L-671,329, a new antifungal agent. I. Fermentation and isolation.
TLDR
A new lipopeptide antifungal agent, similar to echinocandin B, has been isolated from Zalerion arboricola and studies indicate that L-671,329 is produced under both solid and liquid fermentation conditions. Expand
Resistance of yeasts to azole-derivative antifungals.
  • F. Odds
  • Biology, Medicine
  • The Journal of antimicrobial chemotherapy
  • 1993
TLDR
It must be a matter for concern that, by analogy with the known emergence of antibiotic-resistance among bacteria, that the widespread use of a drug inactive against a particular species may lead to an increased incidence of such infections. Expand
Challenges in antibacterial and antifungal drug discovery
TLDR
This chapter discusses challenges in antibacterial and antifungal drug discovery and discusses Amphotericin, which is very potent and has broad spectrum activity against both yeasts and filamentous fungi. Expand
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
TLDR
This review summarizes the factors that contribute to antifungal drug resistance on three levels: clinical factors that result in the inability to successfully treat refractory disease; cellular factors associated with a resistant fungal strain; and molecular factors that are ultimately responsible for the resistance phenotype in the cell. Expand
...
1
2
3
4
5
...